IL96579A0 - Malaria vaccine - Google Patents

Malaria vaccine

Info

Publication number
IL96579A0
IL96579A0 IL96579A IL9657990A IL96579A0 IL 96579 A0 IL96579 A0 IL 96579A0 IL 96579 A IL96579 A IL 96579A IL 9657990 A IL9657990 A IL 9657990A IL 96579 A0 IL96579 A0 IL 96579A0
Authority
IL
Israel
Prior art keywords
malaria vaccine
malaria
vaccine
Prior art date
Application number
IL96579A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Us Army filed Critical Smithkline Beecham Corp
Publication of IL96579A0 publication Critical patent/IL96579A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445Plasmodium
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL96579A 1989-12-08 1990-12-06 Malaria vaccine IL96579A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44774689A 1989-12-08 1989-12-08

Publications (1)

Publication Number Publication Date
IL96579A0 true IL96579A0 (en) 1991-09-16

Family

ID=23777585

Family Applications (1)

Application Number Title Priority Date Filing Date
IL96579A IL96579A0 (en) 1989-12-08 1990-12-06 Malaria vaccine

Country Status (18)

Country Link
EP (1) EP0432965A1 (no)
JP (1) JPH0673097A (no)
KR (1) KR910011897A (no)
CN (1) CN1053814A (no)
AU (1) AU634837B2 (no)
CA (1) CA2031468A1 (no)
FI (1) FI906051A (no)
HU (1) HUT56882A (no)
IE (1) IE904412A1 (no)
IL (1) IL96579A0 (no)
MA (1) MA22097A1 (no)
MY (1) MY105313A (no)
NO (1) NO905301L (no)
NZ (1) NZ236357A (no)
PL (1) PL288140A1 (no)
PT (1) PT96132A (no)
ZA (1) ZA909838B (no)
ZW (1) ZW19090A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ233255A (en) * 1989-04-11 1993-02-25 Chiron Corp Plasmodium cs protein analogues lacking one or more of the repeat epitopes, and containing at least one nonrepeat flanking epitope
US5972351A (en) * 1992-04-03 1999-10-26 Isis Innovation Limited Plasmodium falciparum MHC class I-restricted CTL epitopes derived from pre-erythrocytic stage antigens
ES2127829T3 (es) * 1992-07-31 1999-05-01 Medeva Holdings Bv Expresion de proteinas recombinantes fusionadas en bacterias atenuadas.
GB9401787D0 (en) 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccine compositions
JPH09500540A (ja) * 1993-07-30 1997-01-21 メデヴァ ホールディングス ビー.ヴイ. ワクチン組成物
WO1995007094A1 (en) * 1993-09-10 1995-03-16 New York University Compositions and methods for inhibiting hepatocyte invasion by malarial sporozoites
GB2295394B (en) * 1994-01-31 1997-09-24 Medeva Holdings Bv DNA encoding a fusion protein comprising the C fragment of tetanus toxin
GB9401795D0 (en) * 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccines
AP1925A (en) * 2002-11-20 2008-12-08 Sanara Inc Method for the prevention of malaria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN86100979A (zh) * 1985-02-07 1986-12-17 史密丝克莱恩贝克曼公司 疟疾疫苗的制备方法
IT1196501B (it) * 1986-07-16 1988-11-16 Eniricerche Spa Polipeptide utile per la preparazione di vaccini per la malaria e di kits diagnostici per la determinazione di affezioni malariche
WO1988005817A1 (en) * 1987-01-30 1988-08-11 Smith Kline - Rit S.A. Expression of the p. falciparum circumsporozoite protein by yeast
CA2015722A1 (en) * 1989-05-03 1990-11-03 Mitchell S. Gross Malaria vaccine

Also Published As

Publication number Publication date
CN1053814A (zh) 1991-08-14
MA22097A1 (fr) 1991-12-31
EP0432965A1 (en) 1991-06-19
NO905301D0 (no) 1990-12-07
IE904412A1 (en) 1991-06-19
ZA909838B (en) 1992-05-27
NZ236357A (en) 1993-01-27
NO905301L (no) 1991-06-10
HUT56882A (en) 1991-10-28
PT96132A (pt) 1991-09-30
MY105313A (en) 1994-09-30
JPH0673097A (ja) 1994-03-15
AU634837B2 (en) 1993-03-04
FI906051A (fi) 1991-06-09
HU908128D0 (en) 1991-06-28
PL288140A1 (en) 1991-10-21
KR910011897A (ko) 1991-08-07
ZW19090A1 (en) 1991-04-10
FI906051A0 (fi) 1990-12-07
CA2031468A1 (en) 1991-06-09
AU6777490A (en) 1991-06-13

Similar Documents

Publication Publication Date Title
EP0383833A4 (en) Vaccines for malaria
GB8907914D0 (en) Vaccine preparation
GB8924438D0 (en) Vaccine composition
ZA90474B (en) Vaccine composition
EP0391997A4 (en) Vaccine
GB8921470D0 (en) Vaccines
ZA902147B (en) Coccidiosis vaccine
HUT41844A (en) Sposob poluchenija vaccine against malaria
IL96579A0 (en) Malaria vaccine
GB8918206D0 (en) Tuberculosis vaccine
GB8918689D0 (en) 25/15 vaccine
AP9000165A0 (en) Vaccine composition
ZW7290A1 (en) Malaria vaccine
GB8912496D0 (en) Vaccines
ZA896372B (en) Vaccine
EP0453452A4 (en) Vaccine
GB8922651D0 (en) Vaccine
ZA909516B (en) Novel vaccine
AU5851390A (en) A malaria vaccine
IL90421A0 (en) Influenza vaccine
ZA88792B (en) Conjugate malaria vaccine
GB8919940D0 (en) Vaccines
GB8914532D0 (en) Vaccines
GB8917942D0 (en) Vaccines
GB8926832D0 (en) Vaccines